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In the present report, a review of the literature on the combination of multiple sclerosis and brain tumours is
performed. Additionally, the frequency of such combination, possible etiopathogenetic mechanisms, current
diagnostic criteria and treatment approaches are reviewed. Furthermore, the case of a 30-year-old man with
multiple sclerosis and anaplastic astrocytoma of the right temporal lobe is described in detail. Specifically, the
patient underwent a series of tests, including laboratory analyses of blood and cerebrospinal fluid, brain MRI in
various modes, MR spectroscopy and excised tumour’s pathohistological and immunohistochemical examina-
tion. Results of the tests are reported here. A staged examination and treatment of the patient allowed the
researchers to perform a correct diagnosis and obtain a satisfactory functional outcome.
1. Introduction
The incidence of multiple sclerosis (MS) in a population varies
widely [1,2]. Of note, according to the WHO classification, there are
currently approximately 100 subtypes of 29 histological variants of
primary central nervous system (CNS) tumours [3,4]. Gliomas make up
to ~70% of all cerebral neoplasms, and glioblastomas are the most
common and malignant histological subtype among them [5]. Ac-
cording to literature, including CBTRUS, 61.5% of all gliomas are
glioblastomas, 18.8% are non-glioblastoma astrocytomas, 10.7% are
oligodendrogliomas, 3.6% are ependymomas, and 5.4% are other
gliomas [6].
The combination of MS and cerebral tumours of glial origin is such
comorbidity has been rarely reported in the scientific literature [7]. It
was first described in 1912 by Bosch [8]. Since 1960, numerous cases
have been described.
MS is considered to be a primary pathology, with subsequent de-
velopment of brain gliomas, frequently of astrocytic origin [9,10]. The
association between MS and non-glioma histological subtypes of cere-
bral tumours has also been described [4]. Nevertheless, assessment of
the true occurrence of brain tumours in MS patients is complex.
In the present article, we describe a rare case of combined MS and a
glial tumour, specifically an astrocytoma.
2. Case presentation
The case presented here involves a 30-year-old man admitted to the
neurology clinic with a 3-week complaint of headache, general weak-
ness and fervescence. Over the previous few weeks, the patient had
been treated by an ENT doctor for pansinusitis. Anamnesis revealed a
history of meningococcal meningitis at the age of 8months. There were
no indications of a burdened family history, professional or household
risk factors. Somatically, the patient had a low-grade fever (37.2 °C).
His neurological status included the asthenic syndrome, horizontal end-
position nystagmus to the right, and hyperanisoreflexia, primarily on
the right. With the goal of identifying the headache’s secondary cause,
the patient underwent maxillary sinuses CT. The latter revealed focal
changes in the right temporal lobe. To clarify the nature of brain dis-
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ease, brain MRI, contrast MRI, and MR spectroscopy were performed
(Fig. 1). Results of this imaging indicated inflammatory brain disease.
Cerebral spinal fluid (CSF) examination indicated increased protein
content (1.2 g/l), and lymphocytes induced cell cytosis. CSF’s ex-
amination for infections revealed antibodies to the following viruses:
type I herpes simplex virus, cytomegalovirus, Epstein-Barr virus and
Coxsackievirus. Based on these results, the patient's status was con-
sidered as viral encephalitis. Therefore, he was treated with IV
Herpevir, followed by Acyclovir orally. He was discharged one month
post-hospitalisation with a clinical response.
Two months post-discharge, the patient's condition deteriorated.
Specifically, he developed painful sensations when looking to the left
and blurred vision in the left eye. Ophthalmoscopy indicated signs of
optic nerve oedema on the left. The patient’s neurological status had a
negative trend: low-amplitude horizontal nystagmus when looking to
the right, high-amplitude rotatory nystagmus when looking to the left,
hyper right anisoreflexia, ankle clonus, Babinski's symptom, bilateral
Chaddock's symptom, and instability during the Romberg test. A brain
MRI indicated a decrease in the right temporal lobe lesion.
Additionally, it revealed multiple 4–6mm lesions of both the frontal
and parietal lobes (enhanced signal) in T2 and FLAIR modes. New le-
sions located supratentorially in the periventricular and juxtacortical
areas accumulated the contrast agent (Fig. 2).
On the basis of the clinical data and the lesions’ nature by MRI
scans, MS was suspected. A CSF examination revealed increased protein
content (464mg/l) and blood/CSF hematoencephalic barrier dis-
turbance. Additionally, intrathecal IgG synthesis and oligoclonal IgG
antibodies were found in the CSF. Such findings suggested a chronic
inflammatory CNS disease. Specifically, the patient was diagnosed with
MS, cerebral form, EDSS. Based on this diagnosis, he was treated with
Fig. 1. Brain MRI and MR spectroscopy. A 5.6× 4.2×3.8 cm T2 hyperintense lesion was visualised in the right temporal lobe and the insula. The lesion had
irregular edges and blurred outlines and involved both the grey and white brain matter (A, B). In the T2 mode, two hyperintensive lesions, over 3mm along the long
axis, were visualised periventricularly in the left hemisphere (C, D). Through T1 post-contrast images, low contrast accumulation was observed along the periphery of
the lesion in the right temporal lobe with cystic cavity in the centre. On the contrary, the left hemisphere lesions did not accumulate contrast (E, F). Spectroscopy in
the perifocal area of the right temporal lobe (around the cystic area) revealed the following characteristics: an increase of a Cho peak, a decrease of NAA and a Cr
peak, an unsharply expressed Lip peak, and an inverted Lac (G) peak. An area of cystic transformation expressed an increase of Lip peak and a decrease of all other
peaks. The identified changes corresponded to inflammation (H).
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IV Solu-Medrol pulse therapy, which gave a clinical response.
However, a repeated aggravation took place after 4months. At that
time, the patient had a generalised convulsive seizure with loss of
consciousness. To identify the cause of the seizure, the patient under-
went a brain MRI (no negative trend). An anticonvulsant
Carbamazepine therapy was prescribed, followed by Levitiracetam,
750mg twice a day.
After 6months, IV enhanced follow-up MRI revealed a negative
trend. Specifically, focal changes in the right temporal lobe in the form
of an increased lesion and an area of perifocal oedema were observed. A
27×23.5mm lump in the right temporal lobe, posterior basal sections
of the right frontal lobe, i.e. the insula, was identified. The lesion was
hyperintense in T2 and FLAIR modes and had a cystic component with
moderate perifocal oedema, a mass effect, and a non-homogeneous
structure (probably of a glial nature). MR spectroscopy indicated ad-
ditional data of the intracerebral tumour, a Gr III glioma (Fig. 3).
The intracerebral tumour of the right temporal lobe with median
growth and expansion into ventricular system was surgically excised.
Microscopic examination revealed an anaplastic oligoastrocytoma
with signs of persistent DNA virus infection and focal demyelination
(Fig. 4).
Tumour cells were positive for the following immunohistochemical
markers: GFAP, IDH-1, Ki-67 (Fig. 5). Based on these findings, an
anaplastic oligoastrocytoma (IDH mutant, malignancy grade III) (WHO
grade III, ICD-O code 9382/3) was diagnosed.
Based on the pathohistological findings on the excised tumour, the
patient underwent a course of radiation therapy one month post surgery
in the right temporal lobe (i.e. the excision area) using a linear accel-
erator (60 Gy dosage, 2 Gy per session). Glioma chemotherapy was not
prescribed because of its possible negative effects on MS. Additionally,
considering active MS’s therapy possible negative effects on tumour
development, follow-ups were performed every 3months.
A 4-month IV enhanced MRI revealed a 60×45×26mm cystic
cavity filled with CSF in the right temporal lobe’s excision area.
Numerous round and oval 3–11mm (in the right semi-oval centre)
lesions (high in T2 and FLAIR) were identified in the following loca-
tions: corpus callosum; deep and subcortical white matter of frontal,
parietal, and temporal lobes; area of the pons; right middle cerebellar
peduncle; and left cerebellar hemisphere. Additionally, small isolated
lesions in the subcortical sections were observed (Fig. 6).
No contrasting of revealed lesions or development of new lesions
was observed. This MRI image corresponds to the inactive stage of
Fig. 2. Sagittal plane MRI: Lesions were identified in both the right (A) and left (B) hemispheres. Axial plane MRI: New T2 hyperintense lesions of different diameters
in the large hemispheres and cerebellum (C–I). IV enhanced MRI: New lesions located juxtacortically (J, K) and a large lesion in the right temporal lobe (L)
accumulated the contrast agent.
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demyelination, with infra- and supra-tentorial lesions (cortical, juxta-
cortical and periventricular). Of note, spinal cord MRI during the pa-
tient’s examination and treatment found no pathological lesions.
As of the time of preparation of this article (18months before sur-
gery), according to clinical data and neuroimaging, there were no signs
of continued tumour growth and MS progression. Neurological status
did not include increased pathological symptoms. No convulsive sei-
zures were reported post surgery. The patient continues to be under
active supervision of a neurologist and a neurosurgeon.
3. Discussion
The global risk of malignant neoplasms’ development in MS patients
is important. MS patients undergo immunomodulatory therapy, which
increases cancer risk in any location [11]. However, current data on the
occurrence of cancer in MS patients are contradictory [12–15].
Malignant brain tumour occurrence and detectability in MS patients
is typically higher than in the general population [16,17]. According to
some authors, systematic analysis of the data did not show increased or
decreased risk of glioma in MS patients, while an increased risk was
found for meningiomas [18].
Common etiopathogenetic factors of malignant brain tumours and
MS cannot be excluded. This applies to ethnic factors and race. Of note,
both gliomas and MS are more common in Caucasians [1,6]. Influences
of infections, viruses, and allergens increase the risk of both MS and
CNS lymphoma development but not glial tumours [19]. No significant
correlations with etiological factors such as age, sex and brain cancer
risk factors have been observed.
Discussions are ongoing on the impact of immunomodulatory
treatment in MS patients on cancerogenesis. According to a recent
study, MS patients receiving immunosuppressants generally have a
higher cancer risk [20].
Currently, brain tumours and MS’s diagnosis are based on clinical
and neuroimaging data [21]. Of all cerebral tumours, MS is frequently
Fig. 3. Negative trend: focal changes in the right temporal lobe in the form of an increased lesion and an area of perifocal oedema. Juxtacortical lesions were
unchanged. T2 mode MRI (A–E). FLAIR mode MRI (F–J). MR spectroscopy in the solid portion (K) of the mass indicated a decrease in the NAA and a relative increase
in the Cho peaks. The Cr peak in the pathological mass’s area did not decrease, and the bases of the Cho and Cr peaks were expanded. Expressed Lip and inverted Lac
peaks. A decrease in the NAA and relative increase in the Cho peaks in the cystic portion (L) of the mass. The Cr peak slightly decreased. Expressed Lip and inverted
Lac peaks.
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masked by primary CNS lymphomas that have similar neuroimaging
parameters [22].
Recent data on possible common genetic determinants of MS,
cancer, and neurodegenerative diseases were made public [23].
Several assumptions indicate the possible relationship between MS
and cerebral neoplasms. Specifically, chronic inflammation causes de-
struction of nerve fibres’ myelin sheaths and hyperproliferation of cells
involved in remyelination [24].
This theory is supported by occasional studies focusing on mor-
phological changes in MS’s brain tissues, when cells with signs of dys-
plasia and intermediate characteristics between reactive glial cells and
tumour cells were detected [25]. Similarly, neurotropic growth factors
stimulate MS’s oligodendrocytes and remyelination recovery, possibly
contributing to neoplastic transformation of nerve glial cells [4].
Additionally, MS patients have a higher incidence of multifocal
gliomas, which can be explained by the Willis theory. Specifically,
neoplastic transformation occurs in two stages. First, changes in brain
parenchyma occur because of MS. Then, external stimuli stimulate
neoplastic transformation.
In line with previous theories, we histologically verified a persistent
DNA virus infection in biopsy cells of the present case.
However, there are insufficient data to understand whether MS af-
fects tumour growth intensity. Diagnosis complexity and neuroimaging
errors are noteworthy. Furthermore, new symptoms may indicate MS’s
clinical progression rather than tumour growth, and vice versa.
Fig. 4. Proliferative reactive changes with an-
giodystonic effects and increased vascular per-
meability, characterised by indirect signs of
persistent non-bacterial infection, focal me-
ningothelium proliferation and effects of sig-
nificant proliferate cells polymorphism with
karyopyknosis. Hematoxylin-eosin, 400× (A): In
the area of brain matter, the following char-
acteristics can be identified as invasion: perivasal
and pericellular tissue oedema, neuronophagy,
satelletosis, astrocyte body hyperplasia, paretic
vasodilation, endothelial cells swelling and pro-
liferation with changed intercellular distances.
Hematoxylin-eosin, 800× (B): Changes in the
nuclei of different cell types characterised by the
presence of fine inclusions and nucleoli can be
considered to be indirect signs of persistent viral
infection. The cellular composition of anaplastic
oligoastrocytomas is represented by the pro-
liferation of both polymorphic astrocytes and
cluster oligodendrocytes. Hematoxylin-eosin,
400× (C): Severe oedema with a formation of
spike-like structures, representing the effects of
focal periaxonal demyelination. Hematoxylin-
pikrofuksin according to Van Gieson, 400X (D).
Fig. 5. Immunohistochemistry: non-uniform cell density and finely-divided degradation of astroglia processes. Immunoreactivity against antibodies to glial fibrillary
acidic protein, with additional hematoxylin staining, 800× (A): proliferating cells (immunopositive nuclei) are strongly polymorphic. Immunoreactivity against Ki-
67 antibody, with additional hematoxylin staining, 800× (B): immunopositive response, characterised by IDH expression in individual tumour astrocytes.
Immunoreactivity against EGFR antibodies, with hematoxylin staining, 800× (C).
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4. Conclusion
Although brain gliomas and MS comorbidity are rare, they have
been previously described in the literature. It is not completely clear
whether their occurrence is accidental or consequential to carcino-
genesis-like pathophysiological mechanisms.
Atypical MS symptoms observed in our clinical case require a more
detailed examination with the application of additional diagnostic
techniques.
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